-
-
-
-
-
-
-
QIAGEN Plans to Launch New Fully Automated Sample to Insight Workflow and an AI-Enabled Risk Stratification Tool to Advance QuantiFERON Latent TB Testing
-
-
-
-
-
-
-
QIAGEN Receives U.S. Clearance for Gastrointestinal Panels on Fully Automated QIAstat-Dx Rise Syndromic Testing System
-
-
-
-
-
-
-
QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million
-
-
-
-
-
-
-
QIAGEN delivers solid Q4 2024 growth ahead of outlook
-
-
-
-
-
-
-
QIAGEN Announces 20-F Annual Report Filing for 2019 Results
-
-
-
-
-
-
-
QIAGEN Reports Results for First Quarter of 2019 and Announces Plans for New $100 Million Share Repurchase Program
-
-
-
-
-
-
-
QIAGEN Announces Details for Completion of Approximately $250 Million Synthetic Share Repurchase
-
100,144 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

